A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
Public ClinicalTrials.gov record NCT00883116. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or doxorubicin) in women with advanced endometrial cancer that has progressed following first-line chemotherapy.
Study identification
- NCT ID
- NCT00883116
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 551 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2009 (Type not available)
- Primary completion
- Jun 2012 (Actual)
- Completion
- Feb 2014 (Actual)
- Last update posted
- Mar 9, 2017
2009 – 2014
United States locations
- U.S. sites
- 28
- U.S. states
- 20
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University Of South Alabama | Mobile | Alabama | 36604 | — |
| Rocky Mountain Gynecologic Oncology | Englewood | Colorado | 80113 | — |
| Peter E. Schwartz, Md | New Haven | Connecticut | 06510-3206 | — |
| Hematology Oncology, P.C. | Stamford | Connecticut | 06902 | — |
| Gynecologic Oncology Assoc.,Inc | Hollywood | Florida | 33021 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Sarasota Memorial Health Care System | Sarasota | Florida | 34239 | — |
| H. Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Georgia Health Science University | Augusta | Georgia | 30912-3335 | — |
| Sudarshan K. Sharma, Md | Hinsdale | Illinois | 60521 | — |
| Central Dupage Hospital Cancer Center | Warrenville | Illinois | 60555 | — |
| St. Vincent Hospital And Health Care Center, Inc. | Indianapolis | Indiana | 46260 | — |
| Hematology And Oncology Specialists, Llc | Marrero | Louisiana | 70072 | — |
| Women'S Health Specialists | Rockville | Maryland | 20852 | — |
| Sparrow Regional Cancer Center | Lansing | Michigan | 48912 | — |
| University Of Minnesota | Minneapolis | Minnesota | 55455-0374 | — |
| Saint Dominic's Gynecologic Oncology | Jackson | Mississippi | 39216 | — |
| Matthew A Powell, Md | St Louis | Missouri | 63110 | — |
| Blumenthal Cancer Center | Charlotte | North Carolina | 28204 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Peggy And Charles Stephenson Oklahoma Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Tulsa Cancer Institute | Tulsa | Oklahoma | 74136 | — |
| Pennsylvania Oncology Hematology Associates | Philadelphia | Pennsylvania | 19106 | — |
| Magee-Womens Hospital Of Upmc Laboratory | Pittsburgh | Pennsylvania | 15213 | — |
| Women & Infants Hospital Of Ri | Providence | Rhode Island | 02908 | — |
| Cancer Centers Of The Carolinas | Greenville | South Carolina | 29615 | — |
| Tennessee Gynecologic Oncology Group, Llc | Chattanooga | Tennessee | 37403 | — |
| University Of Virginia | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00883116, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 9, 2017 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00883116 live on ClinicalTrials.gov.